Urinary PGE-M in colorectal cancer: Predicting more than risk?

Cancer Prevention Research

Volumn 7, Issue 10, 2014, Pages 969-972

  Maresso, Karen Colbert ^a   Vilar, Eduardo ^a   Hawk, Ernest T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COLORECTAL CANCER; COLORECTAL TUMOR; ENDOSCOPY; EVIDENCE BASED PRACTICE; HUMAN; PROSPECTIVE STUDY; REVIEW; RISK MANAGEMENT; SURVIVAL RATE; URINE LEVEL; ADENOMA; COLORECTAL NEOPLASMS; FEMALE; URINE;

ADENOMA; ANTI-INFLAMMATORY AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; PROSTAGLANDINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907543103     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0215     Document Type: Review

References (21)

1. Patterson SL, Colbert Maresso K, Hawk E. Cancer chemoprevention: successes and failures. Clin Chem 2013;59:94-101.
2. National Center for Health Statistics. Hist293. Age-adjusted death rates for 64 selected causes by race and sex: United States, 1950-59 [online]. Available from: http://www.cdc.gov/nchs/data/dvs/hist293-1950-59.pdf.
3. Miniño AM, Xu JQ, Kochanek KD. Deaths: Preliminary Data for 2008. Natl Vital Stat Rep 2010;59:1-52.
4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
5. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-17.
6. Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann BJ, Pee D, et al. Colorectal cancer risk prediction tool for whitemen and women without known susceptibility. J Clin Oncol 2009;27:686-93.
7. Sterz K, Scherer G, Ecker J. A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids. J Lipid Res 2012;53: 1026-36.
8. Wang D, DuBois RN. Urinary PGE-M: A promising cancer biomarker. Cancer Prev Res 2013;6:507-10.
9. Cai Q, Gao YT, Chow WH, Shu XO, Yang G, Ji BT, et al. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol 2006;24:5010-6.
10. Johnson JC, Schmidt CR, Shrubsole MJ, Billheimer DD, Joshi PR, Morrow JD, et al. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol 2006;4:1358-65.
11. Shrubsole MJ, Cai Q, Wen W, Milne G, Smalley WE, Chen Z, et al. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res 2012;5:336-42.
12. Bezawada N, Song M, Wu K, Mehta RS, Milne GL, Ogino S, et al. Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev Res 2014;7:758-65.
13. Dong LM, Shu XO, Gao YT, Milne G, Ji BT, Yang G, et al. Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study. Cancer Epidemiol Biomarkers Prev 2009;18: 3075-8.
14. Kekatpure VD, Boyle JO, Zhou XK, Duffield-Lillico AJ, Gross ND, Lee NY, et al. Elevated levels of urinary prostaglandin E metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients. Cancer Prev Res 2009;2:957-65.
15. Kim S, Taylor JA, Milne GL, Sandler DP. Association between urinary prostaglandin E2 metabolite and breast cancer risk: A prospective, case-cohort study of postmenopausal women. Cancer Prev Res 2013;6:511-8.
16. Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res 2013;6:428-36.
17. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the U.S. Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130-60.
18. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-97.
19. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase- specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochemistry 2004;334:266-75.
20. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79.
21. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.